A high bone marrow plasma cell labeling index in stable plateau–phase multiple myeloma is a marker for early disease progression and death

The plasma cell labeling index (PCLI) is a measure of plasma cell proliferative activity and is an important prognostic factor in newly diagnosed multiple myeloma (MM). Occasionally patients have been observed with stable, plateau phase MM with minimal numbers of residual light-chain–restricted mono...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2001-04, Vol.97 (8), p.2522-2523
Main Authors: Steensma, David P., Gertz, Morie A., Greipp, Philip R., Kyle, Robert A., Lacy, Martha Q., Lust, John A., Offord, Janice R., Plevak, Matthew F., Therneau, Terry M., Witzig, Thomas E.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Bone Marrow - pathology
Disease Progression
Female
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Male
Medical sciences
Middle Aged
Mitotic Index
Multiple Myeloma - mortality
Multiple Myeloma - pathology
Neoplastic Stem Cells - pathology
Plasma Cells - pathology
Prognosis
Retrospective Studies
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The plasma cell labeling index (PCLI) is a measure of plasma cell proliferative activity and is an important prognostic factor in newly diagnosed multiple myeloma (MM). Occasionally patients have been observed with stable, plateau phase MM with minimal numbers of residual light-chain–restricted monoclonal plasma cells, but a high PCLI. No data are available on the outcomes for such patients. Data from 57 patients with plateau phase MM and a marrow PCLI of more than 1.0% were compared with 105 matched control patients with MM with a marrow PCLI of less than 1.0%. All patients had less than 10% total plasma cells on marrow aspirate and biopsy. The median time to progression and overall survival were 8 months and 20 months, respectively, in the high PCLI group versus 39 months and 56 months, respectively, in the low PCLI group (P < .0001). These findings suggest that a high PCLI in patients with apparently stable, plateau phase MM is an adverse parameter that may predict a short time to disease progression and death.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V97.8.2522